Pacific Biosciences of California Stock (NASDAQ:PACB)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$2.44

52W Range

$1.16 - $10.65

50D Avg

$1.75

200D Avg

$2.71

Market Cap

$684.05M

Avg Vol (3M)

$8.03M

Beta

2.04

Div Yield

-

PACB Company Profile


Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. Pacific Biosciences of California, Inc. has a development and commercialization agreement with Invitae Corporation. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Show More

Industry

Medical - Devices

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

796

IPO Date

Oct 27, 2010

Website

PACB Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 22Dec 21Dec 20
Instrument$48.72M$61.32M$34.28M
Product$108.70M$113.50M$65.42M
Consumable$59.98M$52.18M$31.14M
Service And Other$19.61M$17.01M$13.47M

Fiscal year ends in Dec 23 | Currency in USD

PACB Financial Summary


Dec 23Dec 22Dec 21
Revenue$200.52M$128.30M$130.51M
Operating Income$-310.37M$-304.82M$-178.16M
Net Income$-306.74M$-296.93M$-181.22M
EBITDA$-310.37M$-297.18M$-178.07M
Basic EPS$-1.21$-1.32$-0.89
Diluted EPS$-1.21$-1.32$-0.89

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Aug 07, 24 | 7:24 PM
Q1 24May 09, 24 | 12:00 AM
Q4 23Feb 15, 24 | 6:39 PM

Peer Comparison


TickerCompany
CRSPCRISPR Therapeutics AG
TWSTTwist Bioscience Corporation
NTLAIntellia Therapeutics, Inc.
EDITEditas Medicine, Inc.